» Articles » PMID: 21956712

Manipulation of Cellular Redox Parameters for Improving Therapeutic Responses in B-cell Lymphoma and Multiple Myeloma

Overview
Journal J Cell Biochem
Date 2011 Sep 30
PMID 21956712
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Developing novel combined-modality therapeutic approaches based on understanding of the involvement of redox biology in apoptosis of malignant cells is a promising approach for improving clinical responses in B-cell lymphoma and multiple myeloma. Therapeutic modalities that generate reactive oxygen species (i.e., radiation, photodynamic therapy, and specific chemotherapeutic drugs) have been shown to be selectively cytotoxic to malignant B-cells. In this review, we will discuss agents that induce apoptosis in B-cell tumors by oxidative stress. Subsequently, a novel biochemical rationale (based on fundamental differences in cancer vs. normal cell oxidative metabolism) for combining oxidative stressors with radiotherapy and chemotherapy, that may lead to designing of more effective treatment strategies for B-cell malignancies, will be discussed. Besides providing potential curative benefit, such novel therapies could also selectively target and inhibit the emergence of drug-resistance in tumor cells, which is a major determinant of treatment failure in many B-cell malignancies.

Citing Articles

Increased Expression of ITGB 3 in CLL Patient leukemia Cells by Exposure to Cold Physical Plasma and Plasma-treated Medium.

Golpour M, Sohbatzadeh F, Alimohammadi M, Yazdani Z, Fattahi S, Zaboli E Int J Mol Cell Med. 2024; 13(3):248-258.

PMID: 39493511 PMC: 11530951. DOI: 10.22088/IJMCM.BUMS.13.3.248.


Arsenic and Diabetes Mellitus: A Putative Role for the Immune System.

Liu J, Hermon T, Gao X, Dixon D, Xiao H All Life. 2023; 16(1).

PMID: 37152101 PMC: 10162781. DOI: 10.1080/26895293.2023.2167869.


Oxidative Stress and Inflammation in B-Cell Lymphomas.

Sousa-Pimenta M, Estevinho M, Sousa Dias M, Martins A, Estevinho L Antioxidants (Basel). 2023; 12(4).

PMID: 37107311 PMC: 10135850. DOI: 10.3390/antiox12040936.


Modulation of Cellular Redox Parameters for Improving Therapeutic Responses in Multiple Myeloma.

Allegra A, Petrarca C, Di Gioacchino M, Casciaro M, Musolino C, Gangemi S Antioxidants (Basel). 2022; 11(3).

PMID: 35326105 PMC: 8944660. DOI: 10.3390/antiox11030455.


Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity.

Sacco A, Federico C, Todoerti K, Ziccheddu B, Palermo V, Giacomini A Blood. 2021; 138(18):1705-1720.

PMID: 34077955 PMC: 9710471. DOI: 10.1182/blood.2020010572.


References
1.
Armand J, Burnett A, Drach J, Harousseau J, Lowenberg B, San Miguel J . The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib. Oncologist. 2007; 12(3):281-90. DOI: 10.1634/theoncologist.12-3-281. View

2.
Wang S, Davis S, Cerhan J, Hartge P, Severson R, Cozen W . Polymorphisms in oxidative stress genes and risk for non-Hodgkin lymphoma. Carcinogenesis. 2006; 27(9):1828-34. DOI: 10.1093/carcin/bgl013. View

3.
Hofmeister C, Jansak B, Denlinger N, Kraut E, Benson D, Farag S . Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma. Leuk Res. 2007; 32(8):1295-8. DOI: 10.1016/j.leukres.2007.10.020. View

4.
Tohyama Y, Takano T, Yamamura H . B cell responses to oxidative stress. Curr Pharm Des. 2004; 10(8):835-9. DOI: 10.2174/1381612043452947. View

5.
Al-Gayyar M, Eissa L, Rabie A, El-Gayar A . Measurements of oxidative stress status and antioxidant activity in chronic leukaemia patients. J Pharm Pharmacol. 2007; 59(3):409-17. DOI: 10.1211/jpp.59.3.0011. View